Napa Pediatric Drops 80 mg/ml

Napa Pediatric Drop is a trusted Pediatric Drops formulation containing Paracetamol 80 mg/ml. Manufactured by Beximco Pharmaceuticals Ltd, this fever reducer and pain reliever is specifically designed for infants and young children.

Priced at ৳20.00 per unit, it effectively treats multiple conditions including post-vaccination fever, teething pain, flu symptoms, and musculoskeletal discomfort. Its rapid action on central prostaglandin synthesis makes it safer than NSAIDs for pediatric use with minimal gastric irritation.

Dosage Guidelines:

• Below 3 months: 0.5 ml (40 mg) 4 times daily
• 4-11 months: 1 ml (80 mg) every 6 hours
• 1-2 years: 1.5 ml (120 mg) up to 4 doses/day

Store in cool, dark places (15-25°C) and use within 4 weeks of opening. While generally well-tolerated, rare side effects may include skin rashes or blood count changes. Avoid concurrent use with anticonvulsants or alcohol to prevent liver toxicity risks.

As Bangladesh’s leading Paracetamol brand, Napa maintains strict quality control. For alternative formulations, explore Pediatric Drops category or consult physicians about sustained-release options for chronic pain management.

Dosage: 3 months: 0.5ml (40mg), 4-11 months: 1ml (80mg), 1-2 years: 1.5ml (120mg) – 4 times daily. Max 75mg/kg/day. Adjust dose in renal/hepatic impairment. Can be taken with/without food.

Side effects of Napa are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.

Pregnancy Category B. Safe during lactation in therapeutic doses. Avoid prolonged use.

Monitor hepatic function in chronic users. Contraindicated in chronic alcoholism. Maintain 8-hour interval between doses.

Pediatric: Contraindicated <3 months without medical supervision. Geriatric: Max 3g/day. Hepatic/renal impairment: Reduce dose by 50%.

Liver damage is possible in adults who have taken 10 g or more of Napa. Ingestion of 5 g or more of Napa may lead to liver damage if the patient has following risk factors: If the patient is on long term treatment with Carbamazepine, Phenobarbitone, Phenytoin, Primidone, Rifampicin, St John’s Wort or other drugs that induce liver enzymes, or regularly consumes Ethanol in excess of recommended amounts, or is likely to be Glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms: Symptoms of Napa overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Immediate treatment is essential in the management of Napa overdose. Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Napa concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Napa. However, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral Methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.